Exclusive License and Development AgreementExclusive License and Development Agreement • November 4th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of this 3rd day of October, 2014 (“Effective Date”) between Sorrento Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America (“USA”) with its principal offices at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 US (“SORRENTO”), and China Oncology Focus Limited, a company organized and existing under the laws of British Virgin Islands with its registered office at Offshore Incorporations Centre, P.O. BOX 957, Road Town, Tortola, British Virgin Islands (“Lee’s”), an Affiliate of Lee’s Pharmaceutical Holdings Limited with a principal offices at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong.
CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 4th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research
THIS CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this “Consent and Amendment”) is entered into as of February 3, 2014, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Parent”), IGDRASOL, INC., a Delaware corporation (“IgDraSol”), SHERRINGTON PHARMACEUTICALS, INC., a Delaware corporation (“Sherrington”), each with offices located at 6042 Cornerstone Court, Suite B, San Diego, CA 92130, and CONCORTIS
